Breaking News

AstraZeneca to Invest in Shanghai Innovation Center

Will establish a commercial cell therapy manufacturing and supply base, enabling end-to-end cell therapy capabilities in China.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca has announced plans to establish a commercial cell therapy manufacturing and supply base and innovation center in Shanghai, enabling end-to-end cell therapy capabilities in China. The company will build the dedicated commercial cell therapy manufacturing and supply base in the Lingang New Area of ​​the Shanghai Free Trade Zone for the commercial production and supply of autologous CAR-T cell therapies in China and other Asian markets, including AZD0120, a BCMA/CD19 dual-target CAR...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters